The effects of ibandronate on OST and BAP in hepatic carcinoma with bone metastases patients
ZHANG Nannan
LI Jing
YANG Shu
CAO Zhongshu
Abstract：Objective To investigate the prognosis of OST(osteocalcin)and BAP(bone alkaline phosphatase)for he-patic carcinoma with bone metastases patients and valuation of Ibandronate. Methods 16 patients of hepatic carcinoma with bone metastases,22 patients of hepatic carcinoma without bone metastases and 20 patients of hepatic carcinoma without metastases were collected. The hepatic carcinoma with bone metastases group was treated with Ibandronate. To observe the defferences of BAP and OST in three groups and treatment or not. Results The levels of serum OST in hepatic carcinoma with bone metastases group,hepatic carcinoma without bone metastases group and hepatic carcinoma without metastases group were 31. 12 ± 4. 18,13. 00 ± 6. 92,10. 23 ± 1. 34,respectively;And the levels of BAP in three groups were 20. 11 ± 1. 65,11. 41 ± 1. 25,10. 78 ± 1. 35,respectively. The levels of OST and BAP increased significantly in the bone metastasis group(P < 0. 05). Ibandronate Injection reduced the levels of OST and BAP in hepatic carcinoma with bone metastasis group. Conclusion The value of BAP and OST were significantly higher in hepatic carcinoma with bone metastases pa-tients,which can be used as reference index of clinical prediction. Ibandronate Injection was effective in the treatment of bone metastases and the mechanism may be related to reduce the levers of OST and BAP.
Keywords：Hepatic carcinomaBone metastasisOsteocalcinBone alkaline phosphataseIbandronate
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 422-424 )